drugset / Trial / NCT03300960
Usefulness of Medroxyprogesterone Acetate in Follicular Phase in Oocyte Donors. Undergoing Ovarian Stimulation
RandomizedParallel-groupOpen-labelPrevention
Summary
The purpose of this study is to determine whether Medroxyprogesterone Acetate (MPA) administration in follicular phase prevents premature luteinization with equal efficiency as GnRH antagonists and otains similar clinical results in oocyte donation.
Timeline
- Start
- 2017-10-20
- Primary completion
- 2019-06-25
- Completion
- 2019-06-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ganirelix | Protein / enzyme biologic | 0.25 mg | — |
| Subject | medroxyprogesterone acetate | Other / unclassified | 10 mg | Oral |